Q3 Earnings Estimate for Merus Issued By HC Wainwright

Key Points

• HC Wainwright estimates Merus will report a Q3 2025 earnings per share of ($1.31), maintaining a "Strong-Buy" rating on the stock.
• Merus' recent quarterly results show an earnings miss, reporting ($2.23) EPS against a consensus of ($1.17).
• Insider selling activity included COO Peter B. Silverman offloading 25,000 shares for a total of $1.5 million at an average price of $60.00.

Merus N.V. (NASDAQ:MRUS - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Merus in a research note issued to investors on Wednesday, August 6th. HC Wainwright analyst A. Maldonado anticipates that the biotechnology company will post earnings of ($1.31) per share for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus' Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($6.27) EPS, FY2026 earnings at ($5.24) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.36) EPS and FY2029 earnings at $0.16 EPS.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($1.06). Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. The business had revenue of $8.83 million for the quarter, compared to analyst estimates of $9.77 million.

MRUS has been the subject of several other research reports. William Blair restated an "outperform" rating on shares of Merus in a research note on Monday, April 28th. Wall Street Zen cut Merus from a "hold" rating to a "sell" rating in a research note on Sunday, July 20th. BMO Capital Markets set a $110.00 target price on Merus and gave the stock an "outperform" rating in a report on Friday, May 23rd. Needham & Company LLC cut their price target on Merus from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Finally, Wells Fargo & Company decreased their target price on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.50.

Merus Stock Performance

Shares of MRUS traded down $0.83 during trading hours on Monday, hitting $63.77. 584,380 shares of the company were exchanged, compared to its average volume of 883,367. The company has a market cap of $4.82 billion, a PE ratio of -11.59 and a beta of 1.09. The firm's 50 day moving average is $58.22 and its 200-day moving average is $48.93. Merus has a 52 week low of $33.19 and a 52 week high of $67.59.

Institutional Investors Weigh In On Merus

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after buying an additional 300 shares during the period. GF Fund Management CO. LTD. increased its stake in shares of Merus by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 315 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of Merus by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock worth $1,921,000 after acquiring an additional 331 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in shares of Merus by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 13,785 shares of the biotechnology company's stock worth $580,000 after acquiring an additional 361 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company's stock valued at $141,000 after acquiring an additional 362 shares in the last quarter. Institutional investors own 96.14% of the company's stock.

Insider Activity at Merus

In other Merus news, COO Peter B. Silverman sold 25,000 shares of Merus stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $60.00, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 82,500 shares of company stock valued at $4,586,340. Company insiders own 3.70% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.